KILITCH DRUGS (INDIA) LTD.

Kilitch Drugs India Ltd announced that its Board of Directors met on July 28, 2026. The board approved the notice for the 34th Annual General Meeting (AGM) to be held on August 27, 2026, via video conferencing. They also approved the Directors' Report, Corporate Governance Report, and related annexures for the financial year ended March 31, 2026. Mr. Deep Shukla was appointed as the scrutinizer for the AGM voting process. The company also announced the closure of its Register of Members and Share Transfer Books from August 20 to August 27, 2026, for the AGM. Additionally, M/s Arvind Kumar & Co. were re-appointed as Cost Auditors for the financial year 2026-27.

Kilitch Drugs India Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect for designated persons and their immediate relatives until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The specific date for the Board of Directors' meeting to approve these unaudited financial results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, aimed at preventing potential insider trading.

Kilitch Drugs India Ltd has announced the commencement of its Nutraceutical Manufacturing Block at its new plant in Raigad, Maharashtra. The facility, located at 24/2/1/1 Maldev, Pen, Raigad, began operations on June 17, 2026. This marks a significant step in the company's expansion into the nutraceutical sector, potentially boosting its product portfolio and market reach.

Kilitch Drugs India Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 15, 2026. The statutory auditors have issued unmodified audit reports on the standalone and consolidated financial statements for the year ended March 31, 2026.

Kilitch Drugs India Ltd has released its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 15, 2026. The auditor's report on the financial statements expressed an unmodified opinion.

Kilitch Drugs India Ltd has submitted the monitoring agency report for the quarter ended March 31, 2026, in compliance with SEBI regulations. The report, dated May 15, 2026, was issued by Infomerics Valuation and Rating Limited. The report indicates no deviation from the objects of the issue, though ₹1.12 crore remains unutilized from the GCP facility, expected to be utilized in Q1FY27 due to pending capex-related payments and final inspection.

Kilitch Drugs India Ltd has scheduled a Board of Directors meeting on May 15, 2026, to consider and approve the audited financial results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will reopen 48 hours after the financial results are disclosed to the stock exchanges.

Kilitch Drugs India Ltd announced the allotment of bonus equity shares in the ratio of 1:1 at its Board Meeting. The meeting, which commenced at 10:30 hours and concluded at 12:25 hours, also resulted in an increase in the company's paid-up Equity Share capital from 174807820 Rs. to 349615640 Rs.

Kilitch Drugs India Ltd has announced the closure of the trading window for all designated persons and their immediate relatives, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure will be effective from Wednesday, 1% April, 2026 until 48 hours after the declaration of the financial results for the quarter and year ended 31% March, 2026. The date of the board meeting to approve the audited financial results will be intimated in due course.

Kilitch Drugs India Ltd has announced that Tuesday, 24th March, 2026 will be the record date for determining the number of shareholders entitled for bonus equity shares. The ratio of bonus equity shares is 1:1, meaning one bonus equity share of Rs. 10/- for every one equity share of Rs. 10/- held by the shareholders. The deemed date of allotment of Bonus Equity Shares is Wednesday, 25th March, 2026. Shareholders whose names are registered on the Company's register of Members in respect of physical shares and on the Register of beneficial owners maintained by Depositories in respect of the shares held in electronic form as of closing hours of Tuesday, 24th March, 2026 shall be entitled to receive the bonus equity shares.